Stockscreener 앱 받기
1.83
2.81%
0.05
시간 외 거래:
1.83
전일 마감가:
$1.78
열려 있는:
$1.77
하루 거래량:
1.29M
Relative Volume:
0.44
시가총액:
$110.39M
수익:
-
순이익/손실:
$-27.37M
주가수익비율:
-4.0202
EPS:
-0.4552
순현금흐름:
$-25.99M
1주 성능:
+8.28%
1개월 성능:
+8.93%
6개월 성능:
-65.14%
1년 성능:
-40.78%
1일 변동 폭
$1.77
$1.92
1주일 범위
$1.66
$1.92
52주 변동 폭
$1.07
$6.175
Aldeyra Therapeutics Inc Stock (ALDX) Company Profile
명칭
Aldeyra Therapeutics Inc
전화
781-761-4904
주소
131 HARTWELL AVENUE, LEXINGTON, MA
Compare ALDX vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ALDX
Aldeyra Therapeutics Inc
|
1.83 | 106.17M | 0 | -27.37M | -25.99M | -0.4552 |
VRTX
Vertex Pharmaceuticals Inc
|
458.99 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
607.93 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
892.26 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
282.72 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
157.77 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Aldeyra Therapeutics Inc Stock (ALDX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-18 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2024-04-03 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2024-04-02 | 재개 | H.C. Wainwright | Buy |
| 2022-04-27 | 재개 | H.C. Wainwright | Buy |
| 2021-02-08 | 개시 | H.C. Wainwright | Buy |
| 2020-12-16 | 개시 | Berenberg | Buy |
| 2020-10-30 | 개시 | Jefferies | Buy |
| 2020-10-16 | 개시 | BTIG Research | Buy |
| 2020-09-22 | 개시 | Alliance Global Partners | Buy |
| 2020-05-12 | 개시 | Oppenheimer | Outperform |
| 2018-12-04 | 개시 | Citigroup | Buy |
| 2018-09-26 | 재확인 | Cantor Fitzgerald | Overweight |
| 2018-09-13 | 개시 | Janney | Buy |
| 2018-01-26 | 개시 | Seaport Global Securities | Buy |
| 2016-09-26 | 개시 | H.C. Wainwright | Buy |
| 2016-07-01 | 개시 | Stifel | Buy |
| 2015-07-01 | 개시 | Canaccord Genuity | Buy |
| 2015-03-25 | 개시 | Chardan Capital Markets | Buy |
| 2015-03-20 | 재확인 | H.C. Wainwright | Buy |
| 2014-11-18 | 개시 | H.C. Wainwright | Buy |
| 2014-06-19 | 개시 | Aegis Capital | Buy |
모두보기
Aldeyra Therapeutics Inc 주식(ALDX)의 최신 뉴스
Bronstein, Gewirtz & Grossman, LLC Is Investigating Aldeyra Therapeutics, Inc. (ALDX) And Encourages Stockholders to Connect - ACCESS Newswire
Aldeyra appoints Darlene Deptula-Hicks to board of directors By Investing.com - Investing.com Nigeria
Aldeyra Therapeutics (ALDX) grants director options on 73,318 shares - Stock Titan
Aldeyra Therapeutics (ALDX) director receives three new stock option grants - Stock Titan
Aldeyra Therapeutics (ALDX) director receives new stock option awards - Stock Titan
Aldeyra Therapeutics (ALDX) grants board member new stock option awards - Stock Titan
[Form 4] Aldeyra Therapeutics, Inc. Insider Trading Activity - Stock Titan
Aldeyra (ALDX) director granted multiple new stock option awards - Stock Titan
Aldeyra Therapeutics (ALDX) director receives long-dated stock option awards - Stock Titan
Aldeyra Therapeutics (ALDX) director Deptula-Hicks submits initial Form 3 - Stock Titan
Aldeyra Therapeutics, Inc. (ALDX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Aldeyra Therapeutics Adds Independent Director, Affirms Governance Support - The Globe and Mail
Aldeyra Therapeutics CEO, President & Director Acquires 18% More Stock - simplywall.st
CEO, President & Director of Aldeyra Therapeutics Picks Up 18% More Stock - Yahoo Finance
Darlene Deptula-Hicks joins Aldeyra (ALDX) board as audit committee chair - Stock Titan
Aldeyra Therapeutics Appoints Darlene Deptula-Hicks to Board of Directors - BioSpace
What Does Darlene Deptula-Hicks Bring to Aldeyra's Board - Kavout
Aldeyra appoints Darlene Deptula-Hicks to board of directors - Investing.com
Aldeyra Therapeutics eyes FDA feedback as dry eye drug faces make-or-break moment - MSN
Why Did ALDX Stock Tank 70% Today? - Stocktwits
Todd Brady Increases Stake in Aldeyra Therapeutics Inc with Sign - GuruFocus
Todd Brady Increases Stake in Aldeyra Therapeutics Inc with Significant Share Purchase - GuruFocus
Aldeyra Therapeutics CEO Todd Brady buys $418,450 in stock By Investing.com - Investing.com Australia
12 Health Care Stocks Moving In Friday's After-Market Session - Benzinga
Aldeyra Therapeutics CEO Todd Brady buys $418,450 in stock - Investing.com
Aldeyra Therapeutics Insider Bought Shares Worth $418,450, According to a Recent SEC Filing - marketscreener.com
Aldeyra (NASDAQ: ALDX) CEO Todd Brady purchases 250,000 common shares - Stock Titan
3 Promising Penny Stocks With Market Caps Reaching $300M - Sahm
Aldeyra Therapeutics Eyes FDA Feedback as Dry Eye Drug Faces Make-or-Break Moment - inkl
ALDX: Late-stage dry eye program nears key FDA decision, with strong cash and AbbVie partnership - TradingView
Aldeyra Therapeutics Q1 2026 Earnings: Narrower Loss Beats Estimates as Pipeline AdvancesCore Business Growth - newsline.com
Aldeyra Therapeutics CEO to Speak at Jefferies Global Healthcare Conference - GuruFocus
Aldeyra Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference - Business Wire
ALDX Technical Analysis | Trend, Signals & Chart Patterns | ALDEYRA THERAPEUTICS INC (NASDAQ:ALDX) - ChartMill
ALDX Q1 2026 Earnings: Narrower-Than-Expected Loss Highlights Cost Discipline Amid Pipeline ProgressEPS Surprise History - newsline.com
Lawsuit filed for Investors who lost money with shares of Zoetis Inc. (NYSE: ZTS) - openPR.com
ANGI Investors Have Opportunity to Join Angi Inc. Fraud Investigation with the Schall Law Firm - Business Wire
Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) Investor Alert: Deadline in Lawsuit on May 29, 2026 - openPR.com
Gossamer Bio, Inc. (NASDAQ: GOSS) Investor Alert: Deadline in Lawsuit on June 1, 2026 - openPR.com
Aldeyra Therapeutics Faces Class Action Deadline Amid FDA Rejections (ALDX) - GuruFocus
ALDX FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Aldeyra - GuruFocus
ALDX DEADLINEFINAL REMINDER: Bronstein, Gewirtz & Grossman LLC Alerts Aldeyra Therapeutics, Inc. Investors to Participate in the Class Action Lawsuit Today - ACCESS Newswire
Aldeyra Therapeutics Faces Securities Fraud Lawsuit Amid FDA Rej - GuruFocus
ALDX Investors Have Opportunity to Lead Aldeyra Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm - Business Wire
ALDX FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Aldeyra Therapeutics (ALDX) Investors of Securities Class Action Deadline on May 29, 2026 - 巴士的報
ALDX UPCOMING DEADLINE : The Gross Law Firm Alerts Aldeyra - GlobeNewswire
Aldeyra Therapeutics Inc (ALDX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Aldeyra Therapeutics Inc 주식 (ALDX) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| DOUGLAS RICHARD | Director |
Mar 19 '26 |
Buy |
1.40 |
70,000 |
98,000 |
195,000 |
| Alfieri Michael | Principal Financial Officer |
Mar 18 '26 |
Buy |
1.42 |
5,000 |
7,100 |
7,500 |
| Alfieri Michael | Principal Financial Officer |
Aug 13 '25 |
Buy |
5.30 |
2,500 |
13,250 |
2,500 |
| Machatha Stephen | Chief Development Officer |
Aug 11 '25 |
Sale |
5.15 |
22,073 |
113,713 |
221,799 |
2.60%
0.94%
자본화:
|
볼륨(24시간):